Alterity Therapeutics Dispatches SPP Documents to Shareholders
Ticker: PRNAF · Form: 6-K · Filed: Jan 10, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: capital-raise, share-offering, biotechnology, neurodegenerative-diseases
TL;DR
**Alterity is raising capital via an SPP, which could dilute shares but fund drug development.**
AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced on January 10, 2024, that it has dispatched Securities Purchase Plan (SPP) documents to eligible shareholders. This plan, approved at an Extraordinary General Meeting, allows existing shareholders to buy more shares, potentially raising capital for the company's neurodegenerative disease treatments. This matters to investors because it indicates Alterity is seeking to raise additional funds, which could dilute existing shares but also provide necessary capital for its drug development, impacting future stock value.
Why It Matters
This filing signals Alterity Therapeutics is moving forward with a capital raise through its Securities Purchase Plan, which could dilute existing shares but also fund critical research into neurodegenerative diseases.
Risk Assessment
Risk Level: medium — While the SPP provides capital, it also carries the risk of share dilution for existing investors.
Analyst Insight
An investor should monitor the outcome of the Securities Purchase Plan to assess the extent of share dilution and the amount of capital raised, which will impact the company's financial runway for drug development.
Key Players & Entities
- Alterity Therapeutics Limited (company) — the registrant and biotechnology company
- Geoffrey P. Kempler (person) — Chairman of Alterity Therapeutics Limited
- January 10, 2024 (date) — date of the report and announcement
Forward-Looking Statements
- Alterity Therapeutics will successfully raise capital through its Securities Purchase Plan. (Alterity Therapeutics) — medium confidence, target: Q1 2024
- The capital raised will be primarily allocated to advancing its neurodegenerative disease treatments. (Alterity Therapeutics) — high confidence, target: Q2 2024
FAQ
What is the primary purpose of this 6-K filing by Alterity Therapeutics?
The primary purpose of this 6-K filing is to announce that Alterity Therapeutics has dispatched the offer documents for its Securities Purchase Plan (SPP) to eligible shareholders, as stated in Exhibit 99.1.
Which stock exchanges is Alterity Therapeutics listed on, according to the filing?
According to the filing, Alterity Therapeutics is listed on the ASX (ASX: ATH) and NASDAQ (NASDAQ: ATHE).
Who signed this 6-K report on behalf of Alterity Therapeutics and when?
The 6-K report was signed by Geoffrey P. Kempler, Chairman of Alterity Therapeutics Limited, on January 10, 2024.
What type of company is Alterity Therapeutics, based on the filing's description?
Alterity Therapeutics is described as a 'biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases' and a 'development stage enterprise'.
Into which previous registration statements is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-01-10 06:03:22
Filing Documents
- ea191434-6k_alterity.htm (6-K) — 13KB
- ea191434ex99-1_alterity.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-002434.txt ( ) — 37KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Securities Purchase Plan (SPP) Documents Dispatched 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: January 10, 2024 2